Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Large Cap
  • Markets
  • News

AstraZeneca’s Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease

By Vandana Singh
December 11, 9:58 AM
AstraZeneca Plc (NASDAQ: AZN) 

AZN

Read More
1 minute read
  • General
  • Health Care
  • Large Cap
  • M&A
  • Movers
  • News
  • Trading Ideas

Why Is Cigna Stock Trading Higher Today?

By Vandana Singh
December 11, 9:47 AM
Cigna Group (NYSE: CI) shares are trading higher after the company reportedly ended its attempt to negotiate an acquisition deal with rival Humana Inc (NYSE: HUM) after the pair 

CI

Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Large Cap
  • Markets
  • News

Novartis’ Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease

By Vandana Singh
December 11, 8:56 AM
Novartis AG (NYSE: NVS) announced 

NVS

Read More
1 minute read
  • Biotech
  • Exclusives
  • FDA
  • General
  • Health Care
  • Market-Moving Exclusives
  • News
  • Penny Stocks

EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year

By Vandana Singh
December 11, 8:30 AM
Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for 

ALZN

Read More
2 minute read
  • General
  • Health Care
  • M&A
  • News
  • Top Stories

Cigna Drops Humana Merger, Opts For $10 Billion Buyback Strategy

By Bibhu Pattnaik
December 10, 3:00 PM
In a recent development in the health insurance sector, Cigna Corporation (NYSE: CI) has withdrawn from its proposed merger with Humana Inc. (NYSE:

CI

Read More
3 minute read
  • Biotech
  • Health Care
  • Politics
  • Trading Ideas

Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: ‘Could Be Helpful, But They’re Not Going To Be Helpful If People Can’t Afford Them’

By Chris Katje
December 8, 5:07 PM
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs.

ALT

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Small Cap
  • Trading Ideas

FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder

By Vandana Singh
December 8, 2:35 PM
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y

BLUE

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Small Cap
  • Trading Ideas

Why Is Cancers/Metabolic Diseases-Focused Biomea Fusion Stock Trading Lower Today?

By Vandana Singh
December 8, 12:47 PM
Biomea Fusion Inc (NASDAQ: BMEA) announced the poster presentation of long-term 26 weeks follow-up data from the first two cohorts of adults with type 2 diabetes (T2D) enrolled in the ongoing Phase 2 study (COVALENT-111) and data from preclinical ex-vivo 

BMEA

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Penny Stocks

eFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer Study

By Vandana Singh
December 8, 12:43 PM
eFFECTOR Therapeutics Inc (NASDAQ: EFTR) announced new interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 study of zotatifin in patients with estrogen receptor positive (ER+) 

EFTR

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News

Why Is Cancer Focused Intensity Therapeutics Stock Trading Over 100% Today?

By Vandana Singh
December 8, 11:22 AM
Intensity Therapeutics Inc (NASDAQ: INTS) announced that safety, tolerability, efficacy, and immune activation data from its Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented during the 2023 San Antonio 

INTS

Posts pagination

Previous 1 … 101 102 103 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service